Anvisa may vote on maintaining or removing the agenda item for the review of RDC 327/2019, which regulates medicinal cannabis products

Anvisa published on Tuesday, December 3, the agenda for the Public Ordinary Meeting (ROP 20/2025) of the Collegiate Board of Directors (Dicol), scheduled to take place on December 10, 2025, at 9:30 am, at the Agency's headquarters. Among the highlights of the agenda is item 2.6, which deals with the proposal to update the regulation of cannabis products for medicinal use — a review of RDC 327/2019.

The item also includes the result of the analysis of Public Consultation No. 1,316/2025, which gathered contributions on technical and regulatory changes for the sector.

According to the official document, if the item remains on the agenda, the reporting director Rômison Rodrigues Mota will present his vote and open the discussion of the draft for deliberation by the other directors. Each member of Dicol may vote or request a review, which suspends the decision until further analysis.

The deadline for oral statements, videos, and requests for confidentiality ends at 11:59 pm this Friday, December 5.

The review of RDC 327/2019 is considered strategic for the medicinal cannabis sector in Brazil, as it could change rules for manufacturing, importing, commercializing, and sanitary requirements.

For now, the expectation remains: confirmation on staying on the agenda, voting, or request for review will only be known on December 10.